New Anti-VEGF Drugs in Ophthalmology

Curr Drug Targets. 2020;21(12):1194-1200. doi: 10.2174/1389450121666200428101738.

Abstract

This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.

Keywords: Anti-VEGF; abicipar pegol; brolucizumab; conbercept; faricimab; port delivery system; ranibizumab.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Eye Diseases / drug therapy*
  • Humans
  • Ophthalmology / methods
  • Ranibizumab / administration & dosage
  • Ranibizumab / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A
  • KH902 fusion protein
  • abicipar pegol
  • brolucizumab
  • Ranibizumab